Risk Factors for Cardiovascular Disease in Type 1 Diabetes

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group

Abstract

Risk factors for cardiovascular disease (CVD) are well-established in type 2 but not type 1 diabetes (T1DM). We assessed risk factors in the long-term (mean 27 years) follow-up of the Diabetes Control and Complications Trial (DCCT) cohort with T1DM. Cox proportional hazards multivariate models assessed the association of traditional and novel risk factors, including HbA1c, with major atherosclerotic cardiovascular events (MACE) (fatal or nonfatal myocardial infarction [MI] or stroke) and any-CVD (MACE plus confirmed angina, silent MI, revascularization, or congestive heart failure). Age and mean HbA1c were strongly associated with any-CVD and with MACE. For each percentage point increase in mean HbA1c, the risk for any-CVD and for MACE increased by 31 and 42%, respectively. CVD and MACE were associated with seven other conventional factors, such as blood pressure, lipids, and lack of ACE inhibitor use, but not with sex. The areas under the receiver operating characteristics curves for the association of age and HbA1c, taken together with any-CVD and for MACE, were 0.70 and 0.77, respectively, and for the final models, including all significant risk factors, were 0.75 and 0.82. Although many conventional CVD risk factors apply in T1DM, hyperglycemia is an important risk factor second only to age.

Trial registration: ClinicalTrials.gov NCT00360893 NCT00360815.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Figures

Figure 1
Figure 1
Kaplan-Meier survival (event-free) curves (solid lines), and 95% CIs (dashed lines) for MACE (top line) and any-CVD (bottom line), with number of subjects at risk for each at 10, 20, and 30 years of follow-up. The number at risk beyond 23 years declines as a function of staggered entry into the study from 1983 to 1989.

References

    1. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006;29:2528–2538
    1. Livingstone SJ, Looker HC, Hothersall EJ, et al. . Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish Registry Linkage Study. PLoS Med 2012;9:e1001321.
    1. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006;29:798–804
    1. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987;30:144–148
    1. Orchard TJ, Olson JC, Erbey JR, et al. . Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26:1374–1379
    1. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006;55:1463–1469
    1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. Nathan DM, Cleary PA, Backlund JY, et al. .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
    1. The DCCT Research Group The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530–545
    1. The DCCT/EDIC Research Group Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111
    1. The DCCT Research Group Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267–2271
    1. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000;49:626–632
    1. Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group . Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2014;37:39–43
    1. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000;21:552–560
    1. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. 2nd ed. Hoboken, NJ, Wiley, 2011
    1. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, Berlin, Springer, 2000
    1. Claeskens G, Hjort NL. Model selection and Model Averaging. Cambridge, New York, Cambridge University Press, 2008
    1. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997;16:385–395
    1. Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011;378:140–146
    1. Miller RG, Secrest AM, Ellis D, Becker DJ, Orchard TJ. Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2013;36:3999–4006
    1. Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes. Best Pract Res Clin Endocrinol Metab 2014;28:325–338
    1. Tolonen N, Forsblom C, Mäkinen VP, et al. .; FinnDiane Study Group . Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study. Diabetes Care 2014;37:2374–2382
    1. American Diabetes Association Standards of Medical Care in Diabetes—2015 Diabetes Care 2015;38(Suppl.):3S1–S93
    1. May O, Arildsen H, Damsgaard EM, Mickley H. Cardiovascular autonomic neuropathy in insulin-dependent diabetes mellitus: prevalence and estimated risk of coronary heart disease in the general population. J Intern Med 2000;248:483–491
    1. Laing SP, Swerdlow AJ, Slater SD, et al. . Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760–765
    1. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014;383:1973–1980
    1. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57:1542–1551
    1. Mozaffarian D, Benjamin EJ, Go AS, et al. .; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015;131:e29–e322
    1. Ferrara A, Mangione CM, Kim C, et al. .; Translating Research Into Action for Diabetes Study Group . Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care 2008;31:69–74
    1. Larkin ME, Backlund JY, Cleary P, et al. .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group . Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabet Med 2010;27:451–458
    1. Williams K, Tchernof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes 2008;57:3289–3296
    1. Peters SA, Huxley RR, Sattar N, Woodward M. Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. Curr Cardiovasc Risk Rep 2015;9:36.
    1. Costacou T, Evans RW, Orchard TJ. High-density lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol 2011;5:387–394
    1. Meigs JB, Wilson PW, Fox CS, et al. . Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006;91:2906–2912
    1. Conway B, Miller RG, Costacou T, et al. . Adiposity and mortality in type 1 diabetes. Int J Obes 2009;33:796–805
    1. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group . Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008;31:1360–1366
    1. The DCCT Research Group Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415–1427
    1. Williams KV, Erbey JR, Becker D, Orchard TJ; The Epidemiology of Diabetes Complications Study . Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. Diabetes Care 1999;22:1084–1091
    1. Pedersen MM, Christensen CK, Mogensen CE. Long-term (18 year) prognosis for normo- and microalbuminuric type 1 (insulin-dependent) diabetic patients. Diabetologia 1992;35(Suppl.):A60
    1. Matsushita K, Coresh J, Sang Y, et al. .; CKD Prognosis Consortium . Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3:514–525
    1. DCCT/EDIC Research Group Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014;2:793–800
    1. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753
    1. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC Study 30-year follow-up. Diabetes Care 2016;39:790–797

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi